X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

NKTX

Closed

Nkarta inc

1.71
+0.05 (+3.01%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.66
Day's Range: 1.63 - 1.765
Send
When Written:
 
3.56
Nkarta Inc. is a biotechnology company that develops and commercializes cell therapies for cancer treatment. The company's platform technology involves engineering natural killer (NK) cells to target and kill cancer cells. Nkarta is focused on developing off-the-shelf, allogeneic cell therapies that can be administered to patients without the need for donor matching or conditioning chemotherapy. The company's lead product candidate is NKX101, which is being developed for the treatment of relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Nkarta was founded in 2015 and is headquartered in South San Francisco, California.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X